TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort Aromatase inhibitor, Bisphosphonate, Breast cancer, Cancer, Hologic, Longitudinal, Secondary osteoporosis, Spain, Tamoxifen, Treatment (anti-osteoporotic treatments)
Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial Aromatase inhibitor, Bisphosphonate, Breast cancer, Cancer, Hologic, Longitudinal, Risedronate, Secondary osteoporosis, Treatment (anti-osteoporotic treatments), USA
Effects of Exemestane and Tamoxifen treatment on bone texture analysis assessed by TBS in comparison with bone mineral density assessed by DXA in women with breast cancer Aromatase inhibitor, Breast cancer, Cancer, Exemestane, GE-Lunar, Germany, Longitudinal, Secondary osteoporosis, Tamoxifen, Treatment (anti-osteoporotic treatments)